The future is bright for RWE in pharma approvals
The FDA and other regulatory bodies are increasingly willing to accept real-world evidence as part of approvals. Pharma is up to the task
Close log in window
Convincing payers of the value of digital add-ons and of drug/device combinations requires pharma to demonstrate that patients and other sta...
Patient real-world data contains a wealth of potentially valuable information for life sciences commercial teams, if they can filter out the...
China’s healthcare market is ripe for those capable of helping it capture the vast potential of real-world data
Partnering with caregivers can help build a more powerful case for re-imbursement if pharma can gather the right evidence
